Sugi Predict

Sugi Predict / Compounds / SCHEMBL14829403

SCHEMBL14829403

SCHEMBL14829403

CC(C)(C)OC(=O)N1CCOCC1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 5/20 0.49
▸ NR1H3 Q13133 4/20 0.49
▸ RIPK1 Q13546 3/20 0.46
▸ BACE1 P56817 2/20 0.46
▸ TMEM97 Q5BJF2 3/20 0.44
▸ SIGMAR1 Q99720 3/20 0.44
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ SCD5 Q86SK9 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.42
▸ HCRTR2 O43614 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829637 1.00 NR1H2 (0.49) NR1H2NR1H3RIPK1BACE1TMEM97
SCHEMBL13749174 1.00 NR1H2 (0.49) NR1H2NR1H3RIPK1BACE1TMEM97
SCHEMBL14916072 0.89 CFB (0.42) NR1H2NR1H3BACE1USP2SMN1; SMN2
SCHEMBL2386027 0.87 NR1H2 (0.43) NR1H2NR1H3USP2SMN1; SMN2GPR119
SCHEMBL2386023 0.87 NR1H2 (0.43) NR1H2NR1H3USP2SMN1; SMN2GPR119
SCHEMBL21224528 0.87 USP2 (0.41) NR1H2NR1H3BACE1TMEM97SIGMAR1
SCHEMBL3398818 0.87 NR1H2 (0.43) NR1H2NR1H3USP2SMN1; SMN2GPR119
SCHEMBL21682785 0.87 NR1H2 (0.50) NR1H2NR1H3BACE1USP2SMN1; SMN2
SCHEMBL20879577 0.86 NR1H2 (0.46) NR1H2NR1H3RIPK1GPR119HCRTR2
SCHEMBL18394698 0.86 NPC1 (0.47) NR1H2NR1H3USP2SMN1; SMN2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421228-B2 Naphthyridine derivatives as PRC2 inhibitors Mirati Therapeutics, Inc. (US) 2025-09-23 — — US disclosed
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS Mirati Therapeutics, Inc. 2025-09-11 — — US disclosed
US-12371435-B2 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors Mirati Therapeutics, Inc. (US) 2025-07-29 — — US disclosed
US-20250179082-A1 IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER Mirati Therapeutics, Inc. 2025-06-05 — — US disclosed
US-12252493-B2 Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer Mirati Therapeutics, Inc. (US) 2025-03-18 — — US disclosed
WO-2025043191-A1 PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE ORIC PHARMACEUTICALS, INC. (US) 2025-02-27 — — WO disclosed
US-20240398811-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS ORIC PHARMACEUTICALS, INC. 2024-12-05 — — US disclosed
EP-4043466-B1 PRC2 INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-08-21 — — EP disclosed
EP-4404932-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS Oric Pharmaceuticals, Inc. (US) 2024-07-31 — — EP disclosed
CN-112004816-B PRC2 inhibitors 米拉蒂医疗股份有限公司 2024-01-05 — — CN disclosed
WO-2020247475-A1 IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER Mirati Therapeutics, Inc. (US) 2020-12-10 — — WO disclosed
EP-3746446-A1 PRC2 INHIBITORS Mirati Therapeutics, Inc. (US) 2020-12-09 — — EP disclosed
CN-112004816-A PRC2 inhibitors 米拉蒂医疗股份有限公司 2020-11-27 — — CN disclosed
WO-2020219448-A1 NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS Mirati Therapeutics, Inc. (US) 2020-10-29 — — WO disclosed
WO-2019152419-A1 PRC2 INHIBITORS MIRATI THERAPEUTICS, INC (US) 2019-08-08 — — WO disclosed
EP-2751088-B1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2016-04-13 — — EP disclosed
EP-2751088-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2014-07-09 — — EP disclosed
US-8765751-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-01 — — US disclosed
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 — — US disclosed
WO-2013049719-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371435-B2 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors EZH2, BMI1, SUZ12 NR1H2 2504/4885NR1H3 2808/4885RIPK1 2695/4885
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, PLK1 NR1H2 1956/4885NR1H3 1937/4885RIPK1 74/4885
US-12252493-B2 Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer BMI1, EZH2, SUZ12 NR1H2 707/4885NR1H3 785/4885RIPK1 3086/4885
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS EZH2, BMI1, SUZ12 NR1H2 1505/4885NR1H3 1480/4885RIPK1 2893/4885
US-20250179082-A1 IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER BMI1, EZH2, SUZ12 NR1H2 707/4885NR1H3 785/4885RIPK1 3086/4885
US-20240398811-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS EZH2, BMI1, EZH1 NR1H2 574/4885NR1H3 562/4885RIPK1 3588/4885
US-12421228-B2 Naphthyridine derivatives as PRC2 inhibitors BMI1, EZH2, SUZ12 NR1H2 352/4885NR1H3 394/4885RIPK1 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.